130 related articles for article (PubMed ID: 22504691)
1. [Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report].
Manabe M; Mitsuoka S; Umekawa K; Tanaka H; Kimura T; Yoshimura N; Takeda A; Kudoh S; Hirata K
Gan To Kagaku Ryoho; 2012 Apr; 39(4):633-5. PubMed ID: 22504691
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
Takenaka T; Yamagata M; Fukuda A; Sonoda T
BMJ Case Rep; 2011 Sep; 2011():. PubMed ID: 22679236
[TBL] [Abstract][Full Text] [Related]
3. [A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Katono K; Kasajima M; Ishihara M; Hayashi N; Nagashima Y; Igawa S; Masuda N
Gan To Kagaku Ryoho; 2013 Mar; 40(3):375-7. PubMed ID: 23507602
[TBL] [Abstract][Full Text] [Related]
4. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
[No Abstract] [Full Text] [Related]
6. Recovery from carcinomatous meningitis by erlotinib.
Ohara G; Kagohashi K; Kurishima K; Kawaguchi M; Nakayama H; Satoh H
Onkologie; 2011; 34(7):394-5. PubMed ID: 21734429
[No Abstract] [Full Text] [Related]
7. [A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Tanaka H; Inomata M; Hayashi R; Shimokawa K; Tokui K; Okazawa S; Kambara K; Yamada T; Miwa T; Kashii T; Konishi H; Tobe K
Gan To Kagaku Ryoho; 2017 Jul; 44(7):595-597. PubMed ID: 28790264
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
9. A case of choroidal metastasis of lung cancer successfully treated with erlotinib.
Fujiu K; Kobayashi N; Miyamoto H; Suzuki H
Gan To Kagaku Ryoho; 2012 Feb; 39(2):269-71. PubMed ID: 22333641
[TBL] [Abstract][Full Text] [Related]
10. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Hata A; Kaji R; Fujita S; Katakami N
J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
[No Abstract] [Full Text] [Related]
11. Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.
Copeman M
J Exp Clin Cancer Res; 2008 Nov; 27(1):59. PubMed ID: 18983643
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Drobnienė M; Cicėnienė A; Zelvienė TP; Grigienė R; Lachej N; Steponavičienė L; Aleknavičius E
Medicina (Kaunas); 2011; 47(9):520-5. PubMed ID: 22156604
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
[TBL] [Abstract][Full Text] [Related]
14. Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Bosch-Barrera J; Sais E; Lorencio C; Porta R; Izquierdo A; Menéndez JA; Brunet J; Sirvent JM; Rosell R
Lung Cancer; 2014 Oct; 86(1):102-4. PubMed ID: 25097032
[TBL] [Abstract][Full Text] [Related]
15. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
16. [Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Fujikura Y; Morishima Y; Ota K; Otsuka S; Homma S; Kurishima K; Hizawa N
Nihon Kokyuki Gakkai Zasshi; 2010 May; 48(5):391-6. PubMed ID: 20560443
[TBL] [Abstract][Full Text] [Related]
17. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
18. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Maruyama K; Chinda J; Kuroshima T; Kabara M; Nakagawa N; Fujino T; Yamamoto Y; Ohsaki Y; Ogawa Y; Hasebe N
Intern Med; 2015; 54(7):823-6. PubMed ID: 25832950
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Uruga H; Moriguchi S; Takahashi Y; Ogawa K; Murase K; Mochizuki S; Hanada S; Takaya H; Miyamoto A; Morokawa N; Kishi K
BMC Cancer; 2018 Aug; 18(1):825. PubMed ID: 30115025
[TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Wagner M; Besse B; Balleyguier C; Soria JC
J Thorac Oncol; 2008 Jun; 3(6):677-9. PubMed ID: 18520813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
